Safety Study of Gene Therapy in Treating Critical Leg Ischemia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-03

Study Completion Date

2023-12-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the safety, tolerability and preliminary efficacy of intramuscular injections of VM202 for subjects with critical limb ischemia.

Subjects selected for this study will have critical limb ischemia that has not responded to standard therapy with symptoms including pain at rest and/or ischemic ulcers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic Drivers,Risk Factors and Management Strategies on Survival and Clinical Outcomes in Visceral Venous "Thrombosis"

NCT07329725

Visceral Venous Thrombosis

ACTIVE_NOT_RECRUITING

Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias

NCT07342413

Leg Veins

NOT_YET_RECRUITING PHASE4

Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis

NCT02414802

Venous Thrombosis

UNKNOWN NA

Vasculaire Compression System Increases Flow Velocity in the Femoral Vein

NCT01240330

Venous Thrombosis

COMPLETED NA

Management of Endothelial Dysfunction in Patients With Chronic Venous Insufficiency After Endovenous Surgical Procedure

NCT04180137

Venous Insufficiency of Leg Venous Insufficiency (Chronic)(Peripheral) Endothelial Dysfunction

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will consist of four (4) cohorts with a total of 3 subjects enrolled in each cohort to VM202.For each dose cohort, VM202 will be administered as a local intramuscular injection in 2 divided doses with a 2-week interval between the injections. Preliminary efficacy (hemodynamic assessments), safety and tolerability will be evaluated at Baseline (screening) and at designated time points throughout the study.

After the first subject in each cohort completed Day 30 (±2 days), and before the Day 15 dosing of the other 2 subjects in the same cohort, an interim safety evaluation was performed with the submission of safety data to the Data Safety Monitoring Committee.

All four dose cohorts will be followed for up to 5 years from the time of the first dose of study drug administration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critical Limb Ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

2 mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.

Group Type EXPERIMENTAL

VM202 2 mg

Intervention Type BIOLOGICAL

2 mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15

Cohort 2

4 mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.

Group Type EXPERIMENTAL

VM202 4 mg

Intervention Type BIOLOGICAL

4 mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15

Cohort 3

8 mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.

Group Type EXPERIMENTAL

VM202 8 mg

Intervention Type BIOLOGICAL

8 mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.

Cohort 4

16 mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.

Group Type EXPERIMENTAL

VM202 16 mg

Intervention Type BIOLOGICAL

16 mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VM202 2 mg

2 mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15

Intervention Type BIOLOGICAL

VM202 4 mg

4 mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15

Intervention Type BIOLOGICAL

VM202 8 mg

8 mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.

Intervention Type BIOLOGICAL

VM202 16 mg

16 mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, between 20 and 90 years of age
* Have critical limb ischemia (Rutherford Class 4 and 5) and considered not a candidate for bypass graft surgery or percutaneous angioplasty due to co-morbid conditions, failure of previous surgical or interventional procedures or caliber of grafting arteries. Critical Limb ischemia is defined as

1. Stable symptoms on standard therapy including anti-platelet agents, vascular rheologic agents, cilostazol, anticoagulant and pain medication for 30 days.
2. Pain at rest and/or ischemic ulcers for a minimum of 4 weeks.
* Have diagnostic angiography of the affected limb in the last 12 months demonstrating a significant occlusion of one more of the following arteries: iliac, superficial femoral, popliteal, and one or more infra-popliteal arteries.
* Have a resting ankle systolic pressure (in either the dorsalis pedis or posterior tibial arteries) of less than or equal to 60mmHg or a resting toe systolic pressure of less than or equal to 40 mmHg in the affected limb.
* Be willing to maintain current drug therapy for peripheral arterial disease throughout the course of the study including anti-platelet and statin inhibitor treatment
* Be capable of understanding and complying with the protocol and signing the informed consent document prior to being subjected to any study related procedures
* Women who are surgically sterile or at least 1 year postmenopausal or who have been practicing adequate contraception for at least 12 weeks prior to entering the study. If the subject is of child-bearing potential, she must have a negative serum pregnancy test result prior to study enrollment and must agree to repeat pregnancy screening tests during the study
* If the subject or the subject's partner(s) is of child bearing potential, the subject and the subject's partner(s) must agree to use a "double barrier" method of birth control while participating in this study.

Exclusion Criteria

* Subjects who have undergone a revascularization procedure or sympathectomy within 12 weeks prior to study entry that remains patent. A failed revascularization procedure in the previous 4 weeks is acceptable.
* Subjects with grade 3 (hemorrhages, exudates) or grade 4 (papilledema) retinopathy.
* Subjects currently receiving immunosuppressive medications, chemotherapy, radiation therapy.
* Subject with aorta-iliac occlusion (greater than 75%).
* Subjects that will require amputation within 4 weeks of randomization.
* Subjects with any co-morbid conditions likely to interfere with assessment of safety or efficacy or with an estimated life expectancy of less than 6 months
* Subjects with history of drug (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within the past 3 months.
* Subjects with a current history or new screening finding of malignant neoplasm except for basal cell carcinoma of the skin and squamous cell carcinoma of the skin (if excised and no evidence of recurrence).
* Subjects with evidence of active infection (e.g. cellulitis, osteomyelitis) or deep ulceration exposing bone or tendon in the extremity planned for treatment.

1. Hemoglobin less than 9.0 g/dL
2. White Blood Cell count less than 3,000 cells/mm3
3. Platelet count less than 75,000 platelets/uL
4. Fasting glucose greater than 250 mg/dL
5. AST and/or ALT greater than 3X upper limit of normal
* Subjects with any other condition that in the opinion of the investigator might put the subject at risk or interfere with his/her participation.
* Subjects unwilling or unable to comply with the protocol or to cooperate fully with the investigator or site personnel.
* Subjects that have received any other investigational drug within the 30 days prior to study drug administration or will receive such a drug during the time frame of this study.
* Subjects with uncontrolled hypertension defined as systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 115 mmHg at Baseline evaluation.
* Subjects with advanced liver disease including decompensated cirrhosis, jaundice, ascites, or bleeding varices.

Minimum Eligible Age

20 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No